SCHEMBL16401261

SCHEMBL16401261

C=CC(O)CCc1cc(C)nc(OC)c1C#N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.40
KDM4E B2RXH2 10/20 0.39
ALDH1A1 P00352 7/20 0.39
HPGD P15428 7/20 0.39
GAA P10253 3/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.35
HTT P42858 2/20 0.35
PKM P14618 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SQOR Q9Y6N5 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16401297 0.83 RECQL (0.44) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16400992 0.81 RECQL (0.42) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16401303 0.80
SCHEMBL4062552 0.80 ALDH1A1 (0.48) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16401343 0.79 RECQL (0.39) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16401899 0.78 RECQL (0.50) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16401095 0.75 RECQL (0.50) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16401867 0.74 KDM4E (0.50) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL16401093 0.72 RECQL (0.40) RECQLKDM4EALDH1A1HPGDGAA
SCHEMBL4070239 0.71 HSD17B10 (0.46) RECQLKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160122342-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-05 US disclosed
US-20160122342-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-05 US disclosed
EP-3004096-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2016-04-13 EP disclosed
WO-2014195919-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122342-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 RECQL 3615/4885KDM4E 55/4885ALDH1A1 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.